glp-1 and mcas Not all GLP-1s work the same way for MCAS. Most patients do better on Tirzepatide, the dual incretin with both GIP receptor agonists. But some mast cells just respond better GLP-1 for MCAS: Addressing Gastroparesis

95.4% of patients lost at least 5% of body weight, 82.0% lost at least 10%, and 32.8% lost at least 20%

How long does the heart rate increase last on retatrutide

However, lifestyle changes including diet, exercise, and behavior adjustments remain a key strategy, typically leading to 510% weight loss

Resting energy expenditure may decline with weight loss (adaptive thermogenesis), making weight regain more likely without ongoing support

Conversely, T2DM appears to reduce ALS risk in older adults (810), though this may reflect effects of insulinotropic medications rather than diabetes itself (11)

Beyond neurodegeneration, GLP-1RAs are being investigated for broader neurological conditions, including stroke and traumatic brain injury, due to their neuroprotective and anti-inflammatory properties [69,70]